FDA Clears Mediso’s Nuclear Medicine Image Processing Software

The US FDA has granted clearance to Mediso for the company’s InterView FUSION and InterView XP multimodality (PET/SPECT/MRI/CT) image processing and reporting software, which is specifically adapted for nuclear medicine and molecular imaging workflows.

The vendor-independent InterView software offers a complete solution for image visualization, post-processing and reporting specifically adapted for the routine nuclear medicine and molecular imaging workflow. Workflows and specialized tools cover the most common nuclear medicine studies including bone, cardiac, central nervous system, thyroid, parathyroid, kidney, liver, digestive system and lung. Fast and standardized reporting is available for all nuclear medicine procedures. The software improves SPECT image quality with iterative reconstruction and reach absolute quantitation with Tera-Tomo SPECT reconstruction engine, making fast and accurate personalized dosimetry possible. It also features a variety of modules to enhance clinical and preclinical research work such as automatic lesion detection, and automatic segmentation and image denoising. The InterView software integrates to any hospital information system either running on stand-alone workstation, or on physical or virtualized server.

"Receiving the FDA nod for our image processing software marks the next step in marketing our clinical products in the USA," said Istvan Bagamery, founder and CEO of Mediso. "The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application and they demonstrate our continuous commitment to the molecular imaging market."